The B-MaP-C study (Breast Cancer Management Pathways During The COVID-19 Pandemic – A National Audit)

The B-Map-C investigated alterations to breast cancer management during the peak transmission period of the UK COVID-19 pandemic (March to May 2020). 64 UK breast units participated (n=3776) with 59% determined to have had ‘COVID-altered’ management. However, the majority of ‘COVID-altered’ management decisions were largely in line with pre-COVID evidence-based guidelines, implying that breast cancer outcomes are unlikely to be negatively impacted.

Classifications: Service Guidance

Keywords: COVID-19